NL300377I1 - Door fluor gesubstitueerde cycloalkaanindolen en hagonisten et gebruik ervan als prostaglandine D2-receptorant - Google Patents

Door fluor gesubstitueerde cycloalkaanindolen en hagonisten et gebruik ervan als prostaglandine D2-receptorant

Info

Publication number: NL300377I1
Authority: NL; Netherlands
Prior art keywords: receptorant; hagonists; indoles; prostaglandin; fluoro
Prior art date: 2002-01-24

Application number

NL300377C

Other languages

English (en)

Other versions

NL300377I2 (nl

Original Assignee

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-24

Filing date

2009-02-20

Publication date

2009-05-06

2009-02-20 Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd

2009-05-06 Publication of NL300377I1 publication Critical patent/NL300377I1/nl

2009-08-03 Publication of NL300377I2 publication Critical patent/NL300377I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)

NL300377C 2002-01-24 2009-02-20 Door fluor gesubstitueerde cycloalkaanindolen en het gebruik ervan als prostaglandine D2-receptorantagonisten NL300377I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35138402P	2002-01-24	2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en)	2002-01-24	2003-01-22	Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number	Publication Date
NL300377I1 true NL300377I1 (nl)	2009-05-06
NL300377I2 NL300377I2 (nl)	2009-08-03

Family

ID=27613492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL300377C NL300377I2 (nl)	2002-01-24	2009-02-20	Door fluor gesubstitueerde cycloalkaanindolen en het gebruik ervan als prostaglandine D2-receptorantagonisten

Country Status (39)

Country	Link
US (6)	US20030158246A1 (nl)
EP (3)	EP2045241B1 (nl)
JP (2)	JP4008885B2 (nl)
KR (2)	KR100859230B1 (nl)
CN (3)	CN101092388A (nl)
AR (1)	AR038136A1 (nl)
AT (1)	ATE414690T1 (nl)
AU (1)	AU2003202343B2 (nl)
BR (1)	BR0307050A (nl)
CA (1)	CA2471952C (nl)
CY (3)	CY1108841T1 (nl)
DE (2)	DE60324767D1 (nl)
DK (2)	DK2045241T3 (nl)
DO (1)	DOP2003000566A (nl)
EA (1)	EA006134B1 (nl)
EC (1)	ECSP045203A (nl)
EG (1)	EG24978A (nl)
ES (2)	ES2391747T3 (nl)
FR (1)	FR09C0010I2 (nl)
GE (1)	GEP20074078B (nl)
HR (1)	HRP20040665B1 (nl)
IL (3)	IL162825A0 (nl)
IS (2)	IS2633B (nl)
JO (1)	JO2481B1 (nl)
LU (1)	LU91534I2 (nl)
MX (1)	MXPA04007167A (nl)
MY (1)	MY137040A (nl)
NL (1)	NL300377I2 (nl)
NO (3)	NO327322B1 (nl)
NZ (1)	NZ533786A (nl)
PE (1)	PE20030982A1 (nl)
PL (1)	PL208527B1 (nl)
PT (2)	PT2045241E (nl)
RS (2)	RS51672B (nl)
SI (2)	SI1470107T1 (nl)
TW (1)	TWI259080B (nl)
UA (1)	UA75520C2 (nl)
WO (1)	WO2003062200A2 (nl)
ZA (1)	ZA200404999B (nl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) *	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
CN1791577A (zh) *	2003-05-20	2006-06-21	麦克弗罗斯特加拿大有限公司	氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
WO2005013985A1 (en) *	2003-08-07	2005-02-17	Merck Sharp & Dohme Limited	Treatment for alzheimer's disease and related conditions
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
KR100808742B1 (ko)	2004-03-11	2008-02-29	액테리온 파마슈티칼 리미티드	테트라하이드로피리도인돌 유도체
JP5239071B2 (ja) *	2004-04-02	2013-07-17	メルク・シャープ・アンド・ドーム・コーポレーション	シクロアルカノインドール誘導体の調製のために有用な非対称水素化方法
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) *	2004-11-08	2007-12-27	Tobert Jonathan A	Method of Treating Pathological Blushing
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006068162A1 (ja) *	2004-12-24	2006-06-29	Shionogi & Co., Ltd.	慢性閉塞性肺疾患の治療剤
DK1833791T3 (da)	2004-12-27	2011-10-24	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
US20080139604A1 (en) *	2005-02-17	2008-06-12	Shaun Fitzpatrick	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
CN101160125A (zh) *	2005-04-13	2008-04-09	默克公司	烟酸受体激动剂、含有这样化合物的组合物和治疗方法
JP5064219B2 (ja)	2005-07-22	2012-10-31	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
WO2007010964A1 (ja)	2005-07-22	2007-01-25	Shionogi & Co., Ltd.	Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
US8143285B2 (en)	2005-09-06	2012-03-27	Shionogi & Co., Ltd.	Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
WO2007149312A2 (en)	2006-06-16	2007-12-27	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
SI2051962T1 (sl)	2006-08-07	2012-02-29	Actelion Pharmaceuticals Ltd	Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
WO2008097535A2 (en) *	2007-02-08	2008-08-14	Merck & Co., Inc.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
US8501959B2 (en)	2008-06-24	2013-08-06	Panmira Pharmaceuticals, Llc	Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
US8685999B2 (en)	2008-09-25	2014-04-01	Merck Sharp & Dohme Corp.	Beta carboline sulphonylurea derivatives as EP4 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) *	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
US8882678B2 (en)	2009-03-13	2014-11-11	Atrium Medical Corporation	Pleural drainage system and method of use
DK2558447T3 (da)	2010-03-22	2014-11-10	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazolderivater og deres anvendelse som prostaglandin d2-receptormodulatorer
MY165623A (en)	2011-04-14	2018-04-18	Idorsia Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es)	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) *	2012-03-28	2015-01-21	中国计量学院	合成分离拉洛皮兰及其类似物的方法
FR3000399B1 (fr) *	2012-12-31	2015-03-27	Galderma Res & Dev	Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000395A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
LT3119779T (lt)	2014-03-17	2018-09-10	Idorsia Pharmaceuticals Ltd	Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
MX2016011900A (es)	2014-03-18	2016-12-05	Actelion Pharmaceuticals Ltd	Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
US20180021302A1 (en)	2015-02-13	2018-01-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
CA2993893A1 (en)	2015-09-15	2017-03-23	Idorsia Pharmaceuticals Ltd	Crystalline forms
CN111886315B (zh)	2018-03-19	2023-06-30	三井化学株式会社	显示元件用密封材及其固化物、有机el元件用框密封材以及有机el元件用面密封材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
EP0234708B1 (en)	1986-01-23	1991-02-27	Merck Frosst Canada Inc.	Tetrahydrocarbazole 1-alkanoic acids
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (en)	1993-12-06	1995-06-15	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (en)	1994-07-11	2003-04-16	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (en)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
TR199701667T2 (xx)	1995-06-21	1999-10-21	Shionogi & Co.,Ltd.	�ift �evrimli amino t�revleri ve bu t�revleri i�eren PGD2 antogonisti.
WO1997002289A1 (en)	1995-07-06	1997-01-23	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
PL191760B1 (pl)	1996-12-13	2006-06-30	Shionogi & Co	Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
CN1198649C (zh)	1998-06-03	2005-04-27	盐野义制药株式会社	用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-22 RS YU62404A patent/RS51672B/sr unknown
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/sr unknown
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active Expired - Fee Related
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Withdrawn
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en not_active Ceased
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown

Also Published As

Publication number	Publication date
WO2003062200A3 (en)	2003-12-04
FR09C0010I2 (nl)	2009-12-18
DK1470107T3 (da)	2009-03-09
IL162825A0 (en)	2005-11-20
JP2007186521A (ja)	2007-07-26
JP2005518413A (ja)	2005-06-23
AU2003202343B2 (en)	2007-07-12
ATE414690T1 (de)	2008-12-15
EP1470107B1 (en)	2008-11-19
EA006134B1 (ru)	2005-10-27
CA2471952A1 (en)	2003-07-31
IL162825A (en)	2010-12-30
TW200302090A (en)	2003-08-01
US7317036B2 (en)	2008-01-08
US7618994B2 (en)	2009-11-17
SI2045241T1 (sl)	2012-11-30
UA75520C2 (en)	2006-04-17
EA200400971A1 (ru)	2004-12-30
LU91534I2 (fr)	2009-04-27
DE122009000022I1 (de)	2009-08-06
EP2045241B1 (en)	2012-07-04
RS20100338A (sr)	2011-06-30
PT2045241E (pt)	2012-09-26
DK2045241T3 (da)	2012-10-15
ES2391747T3 (es)	2012-11-29
US20030158246A1 (en)	2003-08-21
IS8887A (is)	2010-03-01
US20060069148A1 (en)	2006-03-30
JP4008885B2 (ja)	2007-11-14
CN1902176A (zh)	2007-01-24
NZ533786A (en)	2006-11-30
MY137040A (en)	2008-12-31
NO20043536L (no)	2004-08-24
ES2316717T3 (es)	2009-04-16
US20080033028A1 (en)	2008-02-07
PE20030982A1 (es)	2003-11-19
CY2009004I1 (el)	2009-11-04
RS51672B (sr)	2011-10-31
GEP20074078B (en)	2007-03-26
EP2295409B1 (en)	2014-07-02
US20100081696A1 (en)	2010-04-01
BR0307050A (pt)	2004-10-26
RS62404A (sr)	2006-12-15
CN101092388A (zh)	2007-12-26
US20120115921A1 (en)	2012-05-10
EG24978A (en)	2011-04-03
DE60324767D1 (de)	2009-01-02
CY1108841T1 (el)	2011-04-06
PL208527B1 (pl)	2011-05-31
IL188844A0 (en)	2009-02-11
WO2003062200A2 (en)	2003-07-31
FR09C0010I1 (nl)	2009-04-17
US20050124680A1 (en)	2005-06-09
CA2471952C (en)	2008-04-01
TWI259080B (en)	2006-08-01
NO327322B1 (no)	2009-06-08
IS7329A (is)	2004-06-21
HRP20040665B1 (en)	2012-11-30
NO20071193L (no)	2004-08-24
KR20070056166A (ko)	2007-05-31
CY2009004I2 (el)	2009-11-04
NO2009013I1 (no)	2009-06-29
NL300377I2 (nl)	2009-08-03
NO2009013I2 (no)	2012-08-27
ZA200404999B (en)	2006-05-31
PT1470107E (pt)	2009-01-30
EP1470107A2 (en)	2004-10-27
KR20040075109A (ko)	2004-08-26
CN101851191A (zh)	2010-10-06
KR100859230B1 (ko)	2008-09-18
SI1470107T1 (sl)	2009-04-30
JO2481B1 (en)	2009-01-20
PL370427A1 (en)	2005-05-30
AR038136A1 (es)	2004-12-29
EP2045241A1 (en)	2009-04-08
DOP2003000566A (es)	2003-09-15
AU2003202343C1 (en)	2003-09-02
IS2633B (is)	2010-06-15
HRP20040665A2 (en)	2005-04-30
EP2295409A1 (en)	2011-03-16
MXPA04007167A (es)	2004-10-29
CY1113330T1 (el)	2016-06-22
ECSP045203A (es)	2004-09-28

Publication	Publication Date	Title
NL300377I1 (nl)	2009-05-06	Door fluor gesubstitueerde cycloalkaanindolen en hagonisten et gebruik ervan als prostaglandine D2-receptorant
EP1549332A4 (en)	2008-06-18	MODIFIED ASIALO INTERFERONE AND ITS USES
DE50304983D1 (de)	2006-10-19	Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
EP1499306A4 (en)	2007-03-28	BICYCLIC AMIDE
DK1383138T3 (da)	2006-10-02	Elektromagnetisk bölgeabsorber
ATE416317T1 (de)	2008-12-15	Flanschverbindung
FR2834738B1 (fr)	2004-10-22	Panneau composite acoustique
DE60323487D1 (de)	2008-10-23	Elektromagnetischer dämpfer
DE60314221D1 (de)	2007-07-19	Raupenfahrzeug
ATE421515T1 (de)	2009-02-15	Carbonsäureamide
DE60331383D1 (de)	2010-04-08	Dämpfer
ITBO20020208A0 (it)	2002-04-19	Unita per il montaggio di componenti su pannelli di legno e simili
ATE501123T1 (de)	2011-03-15	Sulfonylaminopyrazole als pestizide
FI20021414A0 (fi)	2002-07-26	Tiivisterakenne
AT503225A3 (de)	2010-01-15	Holzbautafel
FR2846682B1 (fr)	2005-07-15	Panneau composite isotherme et insonorisant
FR2841929B1 (fr)	2008-02-15	Cadre dormant metallique
CY2022020I2 (el)	2023-01-05	Χρηση διυδροïμιδαζολονων για την αγωγη σκυλων
ATA13132002A (de)	2005-10-15	Zusammenklappbarer torrahmen
DE50300803D1 (de)	2005-08-25	Kolben-Zylinderaggregat
SE0201777D0 (sv)	2002-06-10	Arrangemang vid gångjärn
FI5654U1 (fi)	2002-12-19	Palonpellin tiivisterakenne
FR2853338B3 (fr)	2005-06-24	Panneaux isothermes et isophoniques
EE00358U1 (et)	2003-04-15	Meetod trenazööri kasutamiseks
ITFI20020062U1 (it)	2003-12-09	Sistema per il fissaggio di tende e simili